Progression of Mild Cognitive Impairment to Dementia in Clinic- vs Community-Based Cohorts
2009/09/01 by Sarah Tomaszewski Farias, Dan Mungas, Bruce R. Reed +3 · 30 citations
Medicine · Health Professions · #Dementia and Cognitive Impairment Research #Alzheimer's disease research and treatments #Geriatric Care and Nursing Homes
paper · doi:10.1001/archneurol.2009.106
Abstract
BACKGROUND: Mild cognitive impairment is increasingly recognized as an important public health problem associated with increased risk of developing dementia. Annual conversion rates, however, vary across different studies with clinic samples showing higher rates of conversion than community-based samples. OBJECTIVES: To establish whether the rates of conversion from mild cognitive impairment to dementia differed according to recruitment source and, if so, to investigate factors that might explain this discrepancy. DESIGN: Rates and predictors of conversion were examined in a prospective longitudinal study at a single center. SETTING: Among the participants, 46% were recruited from a clinical setting and 54% were recruited directly through community outreach. PARTICIPANTS: One hundred eleven individuals with mild cognitive impairment were followed up longitudinally for an average of 2.4 years (range, 0.5-4.0 years). MAIN OUTCOME MEASURES: Conversion from mild cognitive impairment to dementia. RESULTS: During the follow-up period, 28 individuals progressed to dementia with a mean (SD) time to conversion of 2.19 (0.72) years. The clinic sample had an annual conversion rate of 13%, whereas the community sample had an annual conversion rate of 3%. In a Cox proportional hazards model, clinic recruitment source alone was associated with an increased hazard of incident dementia (hazard ratio = 3.50; 95% confidence interval, 1.31-9.18; P = .01). When other variables were added to the model, only baseline functional impairment as measured by the Clinical Dementia Rating Scale (and no demographic, cognitive, or neuroimaging variables or mild cognitive impairment subtype) accounted for the differences in conversion rates across the 2 cohorts. CONCLUSIONS: These findings add to the growing literature to suggest that the degree of functional impairment at baseline is an important predictor of conversion to dementia and may help explain differences in findings between epidemiological and clinic-based studies.
Citations
Cited by
- An automatic Alzheimer’s disease classifier based on spontaneous spoken English
- The role of cognitive reserve and depression on executive function in older adults: A 10-year study from the Wisconsin Registry for Alzheimer’s Prevention
- Managing cognitive impairment in patients with chronic obstructive pulmonary disease (COPD) in Saudi Arabia: what are the current practices?
- Mild Cognitive Impairment in Geriatrics
- Classification and Epidemiology of MCI
- Mild cognitive impairment: ten years later. [europepmc]
- MRI predictors of cognitive change in a diverse and carefully characterized elderly population. [europepmc]
- Heterogeneity of cognitive trajectories in diverse older persons. [europepmc]
- Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. [europepmc]
- Outcomes of mild cognitive impairment by definition: a population study. [europepmc]
- The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales. [europepmc]
- Mild cognitive impairment in Parkinson's disease. [europepmc]
- A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. [europepmc]
- Demographic predictors of cognitive change in ethnically diverse older persons. [europepmc]
- The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. [europepmc]
- Classification and epidemiology of MCI. [europepmc]
- Mild cognitive impairment: a concept in evolution. [europepmc]
- Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. [europepmc]
- Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. [europepmc]
- Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. [europepmc]
- The diagnosis and management of mild cognitive impairment: a clinical review. [europepmc]
- The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. [europepmc]
- Early Functional Limitations in Cognitively Normal Older Adults Predict Diagnostic Conversion to Mild Cognitive Impairment. [europepmc]
- Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. [europepmc]
- Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study. [europepmc]
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. [europepmc]
- Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center. [europepmc]
- Nutrition, Physical Activity, and Other Lifestyle Factors in the Prevention of Cognitive Decline and Dementia. [europepmc]
- Associations of Multidomain Interventions With Improvements in Cognition in Mild Cognitive Impairment: A Systematic Review and Meta-analysis. [europepmc]
- Global prevalence of mild cognitive impairment among older adults living in nursing homes: a meta-analysis and systematic review of epidemiological surveys. [europepmc]
Related